Pooled solifenacin overactive bladder trial data: Creation, validation and analysis of an integrated database  by Chapple, Christopher R. et al.
lable at ScienceDirect
Contemporary Clinical Trials Communications 4 (2016) 199e207Contents lists avaiContemporary Clinical Trials Communications
journal homepage: www.elsevier .com/locate/conctcPooled solifenacin overactive bladder trial data: Creation, validation
and analysis of an integrated database
Christopher R. Chapple a, *, Linda Cardozo b, Robert Snijder c, Emad Siddiqui d,
Sender Herschorn e
a Department of Urology, Royal Hallamshire Hospital, Glossop Rd, Shefﬁeld, South Yorkshire S10 2JF, UK
b King's College Hospital, Denmark Hill, London, SE5 9RS, UK
c Astellas Pharma Europe BV, Sylviusweg 62, 2333 BE, Leiden, The Netherlands
d Astellas Pharma Europe Ltd, 2000 Hillswood Dr, Chertsey, Surrey KT16 0PS, Canada
e Department of Surgery/Urology, University of Toronto, 27 King's College Cir, Toronto, Ontario ON M5S, Canadaa r t i c l e i n f o
Article history:
Received 7 July 2016
Received in revised form
26 September 2016
Accepted 10 October 2016
Available online 15 October 2016
Keywords:
Integrated database
Solifenacin
ValidationAbbreviation: ADaM, Analysis Data Model; AE, ad
index; CDISC, Clinical Data Interchange Standards
Mantel-Haenszel; IDB, integrated database; LOCF, last
MedDRA, Medical Dictionary for Regulatory Activiti
PPIUS, Patient Perception of Urgency Scale; SDTM, S
TEAE, treatment emergent adverse event.
* Corresponding author.
E-mail addresses: c.r.chapple@shef.ac.uk (C.R. Cha
uk (L. Cardozo), robert.snijder@astellas.com (R. Snijd
com (E. Siddiqui), Sender.Herschorn@sunnybrook.ca (
http://dx.doi.org/10.1016/j.conctc.2016.10.003
2451-8654/© 2016 The Authors. Published by Elseviera b s t r a c t
Background: Patient-level data are available for 11 randomized, controlled, Phase III/Phase IV solifenacin
clinical trials.
Methods: Meta-analyses were conducted to interrogate the data, to broaden knowledge about sol-
ifenacin and overactive bladder (OAB) in general. Before integrating data, datasets from individual
studies were mapped to a single format using methodology developed by the Clinical Data Interchange
Standards Consortium (CDISC). Initially, the data structure was harmonized, to ensure identical cate-
gorization, using the CDISC Study Data Tabulation Model (SDTM). To allow for patient level meta-
analysis, data were integrated and mapped to analysis datasets. Mapping included adding derived and
categorical variables and followed standards described as the Analysis Data Model (ADaM). Mapping to
both SDTM and ADaM was performed twice by two independent programming teams, results compared,
and inconsistencies corrected in the ﬁnal output. ADaM analysis sets included assignments of patients to
the Safety Analysis Set and the Full Analysis Set.
Results: There were three analysis groupings: Analysis group 1 (placebo-controlled, monotherapy, ﬁxed-
dose studies, n ¼ 3011); Analysis group 2 (placebo-controlled, monotherapy, pooled, ﬁxed- and ﬂexible-
dose, n ¼ 5379); Analysis group 3 (all solifenacin monotherapy-treated patients, n ¼ 6539). Treatment
groups were: solifenacin 5 mg ﬁxed dose, solifenacin 5/10 mg ﬂexible dose, solifenacin 10 mg ﬁxed dose
and overall solifenacin. Patient were similar enough for data pooling to be acceptable.
Conclusions: Creating ADaM datasets provided signiﬁcant information about individual studies and the
derivation decisions made in each study; validated ADaM datasets now exist for medical history, efﬁcacy
and AEs. Results from these meta-analyses were similar over time.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).verse event; BMI, body mass
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Solifenacin, a competitive muscarinic receptor antagonist that
attenuates bladder contraction, was approved in the United States
and the European Union as a treatment for overactive bladder
(OAB) in 2004 [1]. Due to its long elimination half-life of 40e68 h, it
can be given as a single daily dose. Administration is via a ﬂexible-
dose regimen, starting at 5 mg once daily, but, if sufﬁcient beneﬁt is
not attained, dosage may be increased to 10 mg once daily if well
tolerated. This allows better individualized therapy, with the goal of
optimizing efﬁcacy and minimizing side effects.
From the 53 known solifenacin Phase I to IV studies identiﬁed innder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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database. Inclusion criteria were studies of Phase II or above,
monotherapy only (no combination therapy) and not investigator
driven. One study was selected in error (no monotherapy and no
placebo) but was removed prior to analysis, so a total of 11 studies
were included. These 11 clinical trials took place between 2001 and
2008 and were all Phase III and Phase IV studies with a placebo or
active control arm, conducted in Europe (4 studies), US (6 studies)
or Canada (1 study). The data were consolidated into an integrated
database (IDB) to provide the opportunity to interrogate the data,
with the aim of broadening knowledge about solifenacin and also
overactive bladder (OAB) in a broader sense. Other global databases
have been utilized to probe data in a similar fashion [2e4].
Meta-analyses were conducted on the solifenacin IDB to eval-
uate the prognostic/predictive value of baseline patient and disease
characteristics and to identify subpopulations of patients who
might potentially derive beneﬁt from solifenacin. Clinically
important questions were formulated a priori, by an expert panel of
advisors. Questions included: What can an analysis of body mass
index (BMI) tell us e does being overweight or obese make a dif-
ference to efﬁcacy and/or tolerability? What is the impact of older
age? Do men and women react differently to solifenacin? Does
baseline symptomatology/syndrome severity correlate with
magnitude of treatment response? Do any baseline characteristics
predict who will or will not respond to solifenacin? Are patients
who requested an increase from 5 mg to 10 mg after 4 weeks of
treatment different to those who did not when given the oppor-
tunity? Additional objectives of the meta-analyses were to evaluate
solifenacin safety in the overall population and in the various
subpopulations.
This manuscript describes the methodology for the creation and
analysis of the solifenacin IDB including validation of the
methodology.
2. Methods
2.1. Studies
The 11 studies included in themeta-analysis are listed in Table 1,
along with their main features including study codes, citations and
clinical trial registry information (if available). All studies were
conducted in compliance with the International Conference of
HarmonizationdGood Clinical Practice Guidelines and the princi-
ples of the Declaration of Helsinki. Institutional Review Board/In-
dependent Ethics Committee approval was obtained at all sites. All
patients provided written, informed consent prior to enrolment. Of
the 11 studies, 7 were randomized, double-blind, placebo-
controlled studies (Fig. 1). Of these 7 studies, 4 were ﬁxed-dose
studies and 3 studies allowed for the daily dose of solifenacin to
be adjusted between 5 mg and 10 mg for each subject; 4 studies
had an antimuscarinic active control arm. All studies were based on
a 12-week treatment period, except for study 905-EC-002 (SUN-
RISE; 16 weeks), study 905-UC-007 (VOLT; 12 weeks plus up to 24
weeks extension period), VES-001 (VECTOR; 8 weeks). Data from
all studies were cut off at 12 weeks of treatment to make them
comparable. Therefore, VES-001 (VECTOR) was not included in ef-
ﬁcacy meta-analyses. One study (905-UC-007; VOLT) had minimal
efﬁcacy data and was therefore only used for safety analysis.
2.2. Inclusion criteria
Patient inclusion criteria varied a little across studies, but pa-
tients were similar enough for data to be pooled. The following
demographic characteristics were collected for all studies: age as a
continuous variable; age as a categorical variable (18<40 yrs,40<65 yrs, 65<75 yrs, 75 yrs); gender; race; body mass index
(BMI: <25 kg/m2 [normal], 25e<30 kg/m2 [overweight],
30e<35 kg/m2 [obese] and 35 kg/m2 [severely obese]); region
(US/Canada or Europe). BMI data were not available for all studies
because height and weight were not collected for all studies.
Entry criteria were micturitions 8/24 h (plus 3 incontinence
episodes, or 3 urgency episodes in 3 days); however, for some
studies, entry criteria were based on urgency, therefore, for some
patients, micturition frequency was <8/24 h.
In study 905-EC-002, assessment of urgency was graded using
the Patient Perception of Intensity of Urgency Scale (PPIUS),
whereas in all other studies urgency was recorded as such. For
PPIUS, a score of 3 or more was considered an urgency episode.
2.3. Efﬁcacy assessments
Efﬁcacy of solifenacin was assessed via micturition frequency/
24 h, number of urgency episodes/24 h, number of incontinence
episodes/24 h, number of urgency incontinence episodes/24 h,
number of nocturia episodes/24 h and volume voided/micturition.
Endpoint values were based on last observation carried forward
(LOCF). The percent change did not include patients with zero
baseline and zero at endpoint for any of the variables. When vari-
ables were collected in different ways in the different studies, a
remapping process was applied so that a common set of values was
used across studies.
Response to treatment was deﬁned as: mild (25% reduction
from baseline in average number of episodes/24 h); moderate
(50% reduction from baseline in average number of episodes/
24 h); or strong (75% reduction from baseline in average number
of episodes/24 h). Normalization was deﬁned as: reduction to 8
micturitions/24 h on average (in subjects with 8 micturitions/
24 h); reduction to 0 episodes of incontinence, urgency and ur-
gency incontinence (in subjects with baseline >0); and reduction to
1 episode of nocturia.
2.4. Safety assessments
Safety was assessed by evaluation of Treatment-Emergent
Adverse Events (TEAEs), summarized by MedDRA system organ
class and preferred term (MedDRA version 11.1). Incidence and
severity of TEAEs including those of special interest (dry mouth,
constipation, blurred vision, urinary retention, acute urinary
retention), seriousness of TEAEs and relationship to study drug, as
well as evaluation of withdrawal from study drug and withdrawal
from study drug due to AEs were recorded. For study 905-EC-002
(16-week study), AEs collected beyond week 12 were not included
in the meta-analysis. The Cochrane-Mantel-Haenszel (CMH) test
was used for odds ratios of AEs of interest.
2.5. Statistical methods
A random-effects approach was used for inferential analysis on
efﬁcacy data; this was because data were pooled from multiple
studies with various sample sizes and different randomization and/
or dosing schemes, and the methodology needed to account for
heterogeneity across studies to minimize the risk of bias. The effect
sizes in the studies were assumed to be a random sample of a
distribution of true effect sizes.
The choice of the model was driven by the result of a test of
heterogeneity using the classical measure of heterogeneity
Cochran's Q. However, heterogeneity that would lead to the use of a
different model was not found. Heterogeneity across studies was
evaluated by presenting baseline characteristics and efﬁcacy results
by study.
Table 1
Main features of individual solifenacin studies included in the meta-analysis.
Study (Region) ClinicalTrials.gov
identiﬁer
Phase Planned sample size Placebo-
controlled
Double-
blind
Fixed-dose
monotherapy
Citation
905-CL-013 (US) N/A IIIa Placebo (n ¼ 315)
Solifenacin 10 mg (n ¼ 315)
Yes Yes Yes Chu et al., 2009 [6]
905-CL-014 (US) N/A IIIa Placebo (n ¼ 315)
Solifenacin 10 mg (n ¼ 315)
Yes Yes Yes Govier et al., 2010 [8]
905-CL-015 (EU) N/A IIIa Placebo (n ¼ 190)
Tolterodine 2  2 mg (n ¼ 190)
Solifenacin 5 mg (n ¼ 190)
Solifenacin 10 mg (n ¼ 190)
Yes Yes Yes Chapple et al., 2004 [9]
905-CL-018 (EU) N/A IIIa Placebo (n ¼ 190)
Solifenacin 5 mg (n ¼ 190)
Solifenacin 10 mg (n ¼ 190)
Yes Yes Yes Cardozo et al., 2004 [10]
905-EC-001 STAR (EU) NCT00802373 IIIb Tolterodine 4 mg (n ¼ 474)
Solifenacin 5 mg (n ¼ 474)
No Yes No
Flexible
5 mge10 mg
Chapple et al., 2005 [11]
905-EC-002 SUNRISE
(EU)
NCT00801944 IIIb Placebo (n ¼ 154)
Solifenacin 5 mg (n ¼ 462)
Yes Yes No
Flexible
5 mge10 mg
Cardozo et al., 2008 [12]
905-UC-005 VENUS
(US)
NCT00454896 IIIb Placebo (n ¼ 360)
Solifenacin 5 mg (n ¼ 360)
Yes Yes No
Flexible
5 mge10 mga
Karram et al., 2009 [13]
905-UC-006 VERSUS
(US)
NCT00454740 IIIb Single arm
Solifenacin 5 mg (n ¼ 441)
No No No
Flexible
5 mg to 10 mga
Chancellor et al., 2008 [14]
905-UC-007 VOLT (US) NCT00463541 IIIb Single arm
Solifenacin 5 mg (n ¼ 2000)
No No No
Flexible
5 mg to 10 mga
Garely et al., 2006 [15]
905-UC-10 VIBRANT
(US)
NCT00573508 IV Placebo (n ¼ 381)
Solifenacin 5 mg (n ¼ 381)
Yes Yes No
Flexible
5 mg to 10 mga
Vardy et al., 2009 [16]
VES-001 VECTOR (CAN) NCT00431041 IV Oxybutynin IR 5 mg (n ¼ 65)
Solifenacin 5 mg (n ¼ 65)
No Yes Yes Herschorn et al., 2010 [17]
a A reduction from 10 mg to 5 mg was also permitted.
N/A ¼ not available.
There was no requirement for registering these studies on ClinicalTrials.gov at this time.
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ables at endpoint were examined using Odds Ratios and 95% CIs
and ANCOVA of pooled placebo arms of all placebo-controlled
studies. Predictive factors for change in efﬁcacy variables at
endpoint (gender and age) were examined using ANCOVA for
placebo-controlled monotherapy studies. For each response/
normalization rate comparison between groups, a CMH test, con-
trolling for study, was performed.
In order to report cumulative proportions of AEs, withdrawals
from study drug, and withdrawals from study drug due to AEs, the
Study Size-based (SS-based) approach described by Chuang-Stein
and Beltangady [5] was used so that the risk difference wasFig. 1. Studies in thecollapsible across studies without suffering from Simpson's
paradox [6]. In this meta-analysis, special attentionwas given to the
estimation of cumulative proportions of AEs, withdrawals from
study drug, and withdrawals from study drug due to AEs. For the
purpose of visual comparison between cumulative proportions, a
meta-analytic approach was used to adjust the cumulative pro-
portions and account for differences between studies.
2.6. Data integration
The 11 studies included in the IDB took place prior to 2008. In
2009 Astellas implemented a global data standard, fully based onmeta-analysis.
C.R. Chapple et al. / Contemporary Clinical Trials Communications 4 (2016) 199e207202the Clinical Data Interchange Standards Consortium (CDISC) e an
open, multidisciplinary, neutral, non-proﬁt standards developing
organization [7]. Practically, that meant that not all study databases
followed the CDISC standard data structure, but instead followed
locally agreed data standards applicable at the time of the indi-
vidual study. Standards changed during the period in which the
study databases were set-up. Also, some study databases were built
in the US, others in Europe, resulting in different database struc-
tures. These time and location differences resulted in 11 study da-
tabases that were completely different in structure, format, and
code lists.
Another source of variation between studies was the differing
study designs. For example, studies had slightly different inclusion
criteria; ie, some studies did have an inclusion criteria related to
micturition frequency, whereas other studies selected patients on
the basis of urgency. In addition, the study duration between
studies differed, as did the timing for the visits.
Before integrating the 11 studies into one database, all study
datasets of the individual study datasets were mapped towards a
harmonized data model, following the Global standard within
Astellase the CDISC Study Data TabulationModel (SDTM). To do so,
a 6-step approach was taken (Fig. 2):
Step 1 e annotation of the case report form (CRF) pages and
external data not collected on the CRF, for each study in the IDB.
There were roughly 800 annotations to be made. The CRFs were
all paper CRFs, which resulted in fully manual annotation. In this
step, the current variable name and code list was written to the
SDTM variable name and code list.
Step 2 e creation of project-speciﬁc SDTM speciﬁcations, for
example handling of OAB-speciﬁc diary data.
Step 3 e the actual mapping of the CRF to the project-speciﬁc
SDTM speciﬁcations. This mapping was carried out in Excel, as
much as possible, in a format that could be read and understood
by SAS® programs.Fig. 2. Flow for creatinStep 4 e the preparation phase for the programming activities.
Recoding in MedDRA of AEs was done to a single MedDRA
version. Laboratory data, where applicable, were converted to
standard units and standardized normal ranges were applied.
The coding of concomitant medication was re-done using the
same WHO drug dictionary for all studies. For demographics,
code lists for race, gender and age groups were harmonized.
Step 5 e the actual programming. This included extraction of
actual study data from different data management systems that
were used for these studies, transporting the SAS® dataset ﬁles
containing the study. Extracted data were then mapped
following the instructions as created during Step 1 to 3. Some
new variables were derived, such as baseline ﬂags, reference
dates and unique dataset keys.
Step 6 e veriﬁcation:
1. Were all original data mapped to the new SDTM structured
database?
2. Did the newly created database meet the SDTM structure as
speciﬁed by the CDISC organization?
 A tool called OpenCDISC was used to control the structure of
the database
 Study-speciﬁc elements were checked manually
3. Were all data derivations done correctly?
4. Were all data properly imported and were all code lists properly
applied including MedDRA and the WHO drug dictionary?
As SDTM is uniform in its structure, formats and code lists, the
databases of the different studies could be combined into a single
database.
Data values were harmonized to ensure identical categorization,
for example for race. Although the SDTM structured data is useful
for harmonizing data values and data structures, it is not suitable
for actual data analysis. The actual integration of the database was
performed in a slightly different model e the Analysis Data Model
(ADaM). The purpose of ADaM was to provide a frameworkg SDTM datasets.
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efﬁcient analysis of the study results. For the build of the ADaM
datasets, speciﬁcation sheets were created detailing every dataset
and variable. First was identiﬁcation of which domains should be
built to ﬁt the analysis plan. Two domains were created e namely a
domain speciﬁcally for adverse events analysis (ADAE) and a
domain for diary data (ADMD). Each domain contained subject IDs,
treatment arm, demographic information, study results related to
the domain, derived variables and categorical variables. De-
mographic information included age, region, race, height, weight
and gender.
The categorical variables allowed for subgroup analysis, and
could be used as covariates in ANCOVA analysis. Categorical vari-
ables included categories for age groups, BMI categories, baseline
disease severity, and also categories for treatment and pooling.
Mean number of micturitions, incontinence episodes and urgency
episodes are all examples of derivations of the ADMD domain.
Some patients had fewer diary dates than others. It was decided
that a patient needed at least two diary visits for a mean number to
be derived. This optimized the number of patients that could be
used for analysis.
Visits were redeﬁned based on the actual time on treatment.
Redeﬁning of visits was carried out using visit windows. For each
patient, the last, on-treatment result was noted. For the ADAE,
completely or partly missing dates were imputed to understand if
an AE was treatment emergent. Imputation was done using a
worst-case scenario; ie, if it could not be excluded that an AE was
treatment emergent, then it was considered treatment emergent.
No other imputation of missing values was done.Fig. 3. Integration andAs different pooling strategies were used, categorical variables
were created to quickly select those patients that belonged to a
certain pool, including a variable that indicated the treatment arm
for the pooling strategy. For example, for pool 1 it was useful to split
between the two solifenacin doses (5 and 10 mg); however for pool
2 it was only useful to understand if patients received solifenacin or
placebo.
Fig. 3 shows the process of integrating the database. Firstly, data
were mapped towards one single data standard (SDTM). The SDTM
formatted study datasets were integrated into one IDB, to which
derivations were added. The integrated SDTM including the deri-
vations was mapped towards ADaM.2.7. Database validation
Mapping to SDTM and subsequently to ADaM was performed
twice by two completely independent programming teams. Results
of the two programming groups were compared. Any in-
consistencies were investigated and, where necessary, corrected in
the ﬁnal output (Fig. 4). Micturition frequency at endpoint and the
number of patients included in the SAF were examined. ADaM
analysis sets included the Safety Analysis Set: randomized patients
who took 1 dose of double-blind study medication and the Full
Analysis Set: randomized patients who took 1 dose of double-
blind study medication and had a baseline and 1 post-baseline
efﬁcacy assessment. Additional validation was via double pro-
gramming: two programmers programmed the same dataset in-
dependent of each other and then compared the results of the two
outputs created.derivation process.
Fig. 4. Database integration validation.
Table 2
Analysis groups.
Study Analysis group 1
Placebo-controlled,
monotherapy,
ﬁxed-dose (n ¼ 3011)
Analysis group 2
Placebo-controlled,
monotherapy, ﬁxed- and
ﬂexible-dose (n ¼ 5379)
Analysis group 3
All solifenacin
monotherapy-treated
patients only (n ¼ 6539)
905-CL-013 (12 weeks) 10 mg 10 mg 10 mg
905-CL-014 (12 weeks) 10 mg 10 mg 10 mg
905-CL-015 (12 weeks) 5 mg, 10 mg 5 mg, 10 mg 5 mg, 10 mg
905-CL-018 (12 weeks) 5 mg, 10 mg 5 mg, 10 mg 5 mg, 10 mg
905-EC-002 SUNRISE (16 weeks) 5e10 mg 5e10 mg
905-UC-005 VENUS (12 weeks) 5e10 mg 5e10 mg
905-UC-10 VIBRANT (12 weeks) 5e10 mg 5e10 mg
VES-001 VECTOR (8 weeks)a
905-EC-001 STAR (12 weeks)b 5 mg
905-UC-006 VERSUS (12 weeks, open-label) 5e10 mg
905-UC-007 VOLT 12 weeks, open-label) 5e10 mg
a Control was oxybutynin.
b Control was tolterodine.
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There were three analysis groupings (Table 2). Analysis group 1
comprised placebo-controlled, monotherapy, ﬁxed-dose studies
(n ¼ 3011) and contained placebo, solifenacin 5 mg, solifenacin
10 mg and overall solifenacin treatment groups. Analysis group 2
comprised placebo-controlled, monotherapy, pooled, ﬁxed- and
ﬂexible-dose (n ¼ 5379), with placebo, solifenacin 10 mg and
overall solifenacin groups. Analysis group 3 comprised all sol-
ifenacin monotherapy-treated patients (n ¼ 6539). Treatmentgroups were: solifenacin 5 mg ﬁxed dose, solifenacin 5/10 mg
ﬂexible dose, solifenacin 10 mg ﬁxed dose and overall solifenacin.
Patient inclusion criteria varied a little across studies, but patients
were similar enough for pooling of data to be acceptable. Table 3
shows ADaM datasets yielded from integration. When judging
reliability of results from ameta-analysis, attention should focus on
factors that might systematically inﬂuence the overall estimate of
treatment difference. An important factor is the selection of studies
for inclusion, as bias may be introduced by selective exclusion of
some eligible studies. Justiﬁcation for not including all studies in
the pooling groups is as follows: comparisons with placebo
excluded those studies that were not placebo-controlled, to mini-
mize the risk of biased comparison; for example, aggregating re-
sults from a placebo-controlled study with those from a single-arm
study in which subjects responded better on average than in the
active group of the former study would result in a biased treatment
difference towards inﬂation of the treatment effect. Flexible-dose
regimen studies were excluded from dose-speciﬁc comparisons,
since if adjusted doses and ﬁxed doses are pooled, results cannot be
interpreted as being those of a speciﬁc dose. In order to estimate
incidence of rare AEs, all monotherapy studies were included so
that all solifenacin monotherapy-treated subjects were evaluated.
As three different active controls were used in a total of four
studies, active control groups were disregarded.
Since the most speciﬁc comparisons were between ﬁxed doses
of solifenacin and placebo, analysis 1 (placebo-controlled, mono-
therapy, ﬁxed-dose studies) was evaluated as the most adequate
pooling strategy, followed by analysis group 2 (placebo-controlled
studies) as a way to account for all placebo-controlled trials in a
comparison of solifenacin and placebo that disregards dose and
regimen. The third pooling strategy (all solifenacin monotherapy-
treated patients) was utilized to detect rare TEAEs.Although all endpoints were pre-speciﬁed, we recognize the
substantial risk of false positive ﬁndings due to the large number of
endpoints, as no formal adjustment for multiplicity has been
applied; therefore P-values need to be interpreted with caution.
Fig. 5 provides an example of an ADaM dataset. There were
minor differences between ADaM datasets and the original study
reports (Table 4); deviations were expected, due to harmonization
of the studies. For example, there weremore patients in ADaM than
in some study reports because they had sufﬁcient data (2 days),
whereas inclusion in the original analysis demanded 3 diary
Table 3
ADaM datasets yielded from integration.
Analysis group 1
Placebo-controlled,
monotherapy,
ﬁxed-dose (n ¼ 3026)
Analysis group 2
Placebo-controlled monotherapy, ﬁxed
and ﬂexible dose (n ¼ 5396)
Analysis group 3
All solifenacin monotherapy-treated patients only (n ¼ 6534)
Placebo Solifenacin 5 mg Solifenacin 10 mg Placebo Solifenacin all Solifenacin 5 mg Solifenacin 10 mg Solifenacin 5e10 mg
Safety Analysis Set 1216 577 1233 2189 3207 645 1233 4656
40.2% 19.1% 40.7% 40.6% 59.4% 9.9% 18.9% 71.3%
Full Analysis Set 1137 552 1158 2077 3081 620 1158 2389
37.8% 18.3% 38.5% 38.6% 57.3% 14.4% 26.9% 55.6%
Fig. 5. Example of ADaM data.
C.R. Chapple et al. / Contemporary Clinical Trials Communications 4 (2016) 199e207 205entries. These differences were harmonized into one methodology
and therefore ADaM is a valid dataset for analysis.4. Conclusions
Patient-level data from 11 randomized placebo- and/or active-
controlled clinical trials of solifenacin that took place between
2001 and 2008 were consolidated into a large IDB. Analysis group 1
comprised placebo-controlled, monotherapy, ﬁxed-dose studies
(n ¼ 3011), analysis group 2 comprised placebo-controlled, mon-
otherapy, pooled, ﬁxed- and ﬂexible-dose (n ¼ 5379), and analysis
group 3 comprised all solifenacin monotherapy-treated patients
(n ¼ 6539). Creating the ADaM datasets provided a signiﬁcant
amount of information about the individual studies and the deri-
vation decisions made in each study; validated ADaM datasets now
exist for medical history, efﬁcacy, and AEs. Although one might
think that a study performed in 2001 could produce slightly
different results to a study performed in 2008, due to changes in the
population or changes in treatment methods or beliefs in each timeperiod, results from these meta-analyses showed that results were
similar over time.Availability of data and materials
905-CL-013: https://www.astellasclinicalstudyresults.com/hcp/
study.aspx?ID¼905-CL-013
905-CL-014: https://www.astellasclinicalstudyresults.com/hcp/
study.aspx?ID¼905-CL-014
905-CL-015: https://www.astellasclinicalstudyresults.com/hcp/
study.aspx?ID¼905-CL-015
905-CL-018: https://www.astellasclinicalstudyresults.com/hcp/
study.aspx?ID¼905-CL-018
905-EC-001 STAR: https://clinicaltrials.gov/ct2/show/NCT00802
373?term¼NCT00802373&rank¼1
905-EC-002 SUNRISE: https://clinicaltrials.gov/ct2/show/NCT00
801944?term¼NCT00801944&rank¼1
905-UC-005 VENUS: https://clinicaltrials.gov/ct2/show/NCT00
454896?term¼NCT00454896&rank¼1
Table 4
Endpoint mean change for ADaM dataset vs CSR for average micturitions/24 h (differences in bold).
Study Treatment ADaM CSR ADaM ADaM CSR ADaM CSR ADaM CSR ADaM CSR
n n LS mean (SE) Mean
change
Mean LS mean
difference (SE)
LS Mean
difference
P-value P-value 95% CI 95% CI
905-CL-013 Placebo 309 309 1.55 (0.132) 1.52 ¡1.5
Solifenacin 10 mg 305 306 2.96 (0.133) 2.99 ¡3.0 ¡1.41 (0.187) ¡1.5 <0.001 <0.001 (e1.77, 1.04)
905-CL-014 Placebo 295 295 1.26 (0.143) 1.31 ¡1.3
Solifenacin 10 mg 298 298 2.46 (0.142) 2.41 ¡2.4 ¡1.20 (0.202) ¡1.1 <0.001 <0.001 (e1.59, 0.80)
905-CL-015 Placebo 253 253 1.18 (0.177) 1.18 ¡1.20
Solifenacin 5 mg 266 266 2.25 (0.172) 2.21 ¡2.19 1.07 (0.247) ¡1.02 <0.001 <0.001 (e1.55, 0.58) (e1.50, e0.54)
Solifenacin 10 mg 264 264 2.58 (0.173) 2.62 ¡2.61 1.40 (0.247) ¡1.37 <0.001 <0.001 (e1.88, 0.91) (e1.85, e0.89)
905-CL-018 Placebo 280 281 1.64 (0.171) 1.68 ¡1.66
Solifenacin 5 mg 286 286 2.50 (0.169) 2.48 ¡2.45 0.86 (0.240) ¡0.78 <0.001 <0.01 (e1.33, 0.39) (e1.27, e0.29)
Solifenacin 10 mg 290 290 2.91 (0.168) 2.90 ¡2.88 1.27 (0.239) ¡1.22 <0.001 <0.001 (e1.74, 0.80) (e1.71, e0.72)
905-EC-002
SUNRISE
Placebo 216 216 1.24 (0.355) 1.22 ¡1.3
Solifenacin
ﬂexible 5/10 mg
636 637 2.07 (0.324) 2.08 ¡2.0 0.83 (0.480) ¡0.7 0.084 0.001 (e1.77, 0.11) (e1.2, e0.3)
905-UC-005
VENUS
Placebo 347 337 1.84 (0.153) 1.86 ¡1.94
Solifenacin
ﬂexible 5/10 mg
352 348 2.65 (0.152) 2.64 ¡2.67 0.81 (0.215) <0.001 <0.01 (e1.23, 0.39)
905-UC-10
VIBRANT
Placebo 363 363 1.27 (0.151) 1.29 ¡1.36
Solifenacin
ﬂexible 5/10 mg
369 369 2.21 (0.150) 2.19 ¡2.23 0.94 (0.213) ¡0.90 <0.001 <0.001 (e1.36, 0.52) (e1.3, e0.5)
C.R. Chapple et al. / Contemporary Clinical Trials Communications 4 (2016) 199e207206905-UC-006 VERSUS: https://clinicaltrials.gov/ct2/show/NCT00
454740?term¼NCT00454740&rank¼1
905-UC-007 VOLT: https://clinicaltrials.gov/ct2/show/NCT00
463541?term¼NCT00463541&rank¼1
905-UC-10 VIBRANT: https://clinicaltrials.gov/ct2/show/NCT00
573508?term¼NCT00573508&rank¼1
VES-001 VECTOR: https://clinicaltrials.gov/ct2/show/NCT0043
1041?term¼NCT00431041&rank¼1
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